• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rani Therapeutics Holdings Inc.

    3/26/26 4:46:53 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RANI alert in real time by email
    S-8 1 rani-20260326.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on March 26, 2026

     

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Rani Therapeutics Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    86-3114789

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    2051 Ringwood Avenue

    San Jose, California 95131

    (Address of Principal Executive Offices) (Zip code)

     

    Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan

    Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan

    (Full titles of the plans)

     

     

    Talat Imran

    Chief Executive Officer

    Rani Therapeutics Holdings, Inc.

    2051 Ringwood Avenue

    San Jose, California 95131

    (408) 457-3700

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Copies to:

    Josh Seidenfeld

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer 

    Accelerated filer 

    Non-accelerated filer 

    Smaller reporting company 

     

    Emerging growth company 

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     


     

    PART I

    EXPLANATORY NOTE AND GENERAL INSTRUCTION E INFORMATION

    The Registrant is filing this Registration Statement on Form S-8 for the purpose of registering an additional 6,079,622 shares of Class A common stock under the Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan and an additional 100,000 shares of Class A common stock under the Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of Class A common stock reserved for issuance under each respective plan.

    The Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements on Form S-8 of the Registrant relating to the same employee benefit plans set forth herein are effective. Pursuant to General Instruction E of Form S-8, this Registration Statement incorporates by reference the contents of the registration statements on Form S-8 relating to the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan filed by the Registrant with the Securities and Exchange (the “SEC”) on August 3, 2021 (File No. 333-2584150), on March 31, 2022 (File No. 333-264018), on March 22, 2023 (File No. 333-270747) on March 20, 2024 (File No. 333-278116), and on March 31, 2025 (File No. 333-286262).

     


     

    PART II

    Item 3. Incorporation Of Certain Documents By Reference.

    The following documents filed by Rani Therapeutics Holdings, Inc. (the “Registrant”) with the Commission are incorporated by reference into this Registration Statement:

    (a)
    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026;
    (b)
    Our Current Report on Form 8-K filed with the SEC on January 2, 2026; and
    (c)
    The description of the Registrant’s Class A common stock which is contained in a registration statement on Form 8-A filed with the Commission on July 26, 2021 (File No. 001-40672) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All other reports and documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8. Exhibits.

     

     

     

     

     

    Incorporated by Reference

     

     

    Exhibit
    Number

     

    Description

     

    Schedule
    Form

     

    File Number

     

    Exhibit

     

    Filing Date

    4.1

     

    Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.

     

    8-K

     

    001-40672

     

    3.1

     

    January 2, 2026

    4.2

     

    Amended and Restated Bylaws of the Registrant, as currently in effect.

     

    8-K

     

    001-40672

     

    3.2

     

    January 2, 2026

    4.3

     

    Specimen Class A common stock certificate of the Registrant.

     

    S-1/A

     

    333-257809

     

    4.1

     

    July 26, 2021

    5.1*

     

    Opinion of Cooley LLP.

     

     

     

     

     

     

     

     

    23.1*

     

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

     

    23.2*

     

    Consent of Marcum LLP, Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

    23.3*

     

    Consent of CBIZ CPAs P.C., Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

    24.1*

     

    Power of Attorney (included on the signature page of this registration statement).

     

     

     

     

     

     

     

     

    99.1

     

    Rani Therapeutics, LLC 2016 Equity Incentive Plan and forms of agreement thereunder.

     

    S-1

     

    333-257809

     

    10.5

     

    July 9, 2021

    99.2

     

    Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan.

     

    S-1/A

     

    333-257809

     

    10.7

     

    July 26, 2021

    99.3

     

    Forms of Agreement under the Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan.

     

    10-K

     

    001-40672

     

    10.8

     

    March 31, 2022

    99.4

     

    Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan.

     

    S-1/A

     

    333-257809

     

    10.8

     

    July 26, 2021

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

    * Filed herewith

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Jose, State of California, on March 26, 2026.

     

     

    Rani Therapeutics Holdings, Inc.

     

     

     

     

    By:

    /s/ Talat Imran

     

     

    Talat Imran

     

     

    Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Talat Imran and Svai Sanford, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Talat Imran

     

    Chief Executive Officer and Director

     

    March 26, 2026

    Talat Imran

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Svai Sanford

     

    Chief Financial Officer

     

    March 26, 2026

    Svai Sanford

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    /s/ Mir Imran

     

    Chairman of the Board

     

    March 26, 2026

     Mir Imran

     

     

     

     

     

     

     

     

     

    /s/ Dennis Ausiello

     

    Director

     

    March 26, 2026

    Dennis Ausiello

     

     

     

     

     

     

     

     

     

    /s/ Jean-Luc Butel

     

    Director

     

    March 26, 2026

    Jean-Luc Butel

     

     

     

     

     

     

     

     

     

    /s/ Abraham Bassan

     

    Director

     

    March 26, 2026

    Abraham Bassan

     

     

     

     

     

     

     

     

     

    /s/ Vasudev Bailey

     

    Director

     

    March 26, 2026

    Vasudev Bailey

     

     

     

     

     

     

     

     

     

    /s/ Lisa Rometty

     

    Director

     

    March 26, 2026

    Lisa Rometty

     

     

     

     

     

     


    Get the next $RANI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RANI

    DatePrice TargetRatingAnalyst
    8/2/2024$17.00Outperform
    Oppenheimer
    6/14/2024$15.00Buy
    Maxim Group
    6/13/2024$10.00Buy
    Rodman & Renshaw
    4/17/2023$24.00Buy
    BTIG Research
    10/11/2022$15.00Buy
    UBS
    7/27/2022$22.00Buy
    H.C. Wainwright
    6/13/2022$28.00Outperform
    Wedbush
    8/25/2021$24.00Buy
    BTIG
    More analyst ratings

    $RANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Imran Mir A bought $1,260,417 worth of shares (2,083,334 units at $0.60) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/27/25 7:24:25 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Mckinley Kate bought $29,993 worth of shares (17,960 units at $1.67) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/16/24 6:00:49 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Imran Talat bought $19,974 worth of shares (10,296 units at $1.94), increasing direct ownership by 2% to 494,751 units (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    12/10/24 1:12:17 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Javadi Alireza

    3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    3/27/26 7:47:04 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bailey Vasudev Jaiprakash

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/30/25 4:31:44 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Bailey Vasudev Jaiprakash

    3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/30/25 4:30:21 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rani Therapeutics Holdings Inc.

    SCHEDULE 13G/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    3/27/26 11:33:35 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Rani Therapeutics Holdings Inc.

    S-8 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    3/26/26 4:46:53 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Rani Therapeutics Holdings Inc.

    10-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)

    3/26/26 4:43:01 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

    - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – - Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen

    3/26/26 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

    SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. "Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy," said Talat Imr

    3/25/26 4:53:16 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listen

    3/19/26 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Rani Therapeutics with a new price target

    Oppenheimer initiated coverage of Rani Therapeutics with a rating of Outperform and set a new price target of $17.00

    8/2/24 7:39:43 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Rani Therapeutics with a new price target

    Maxim Group initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $15.00

    6/14/24 9:10:16 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rani Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $10.00

    6/13/24 7:14:35 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Leadership Updates

    Live Leadership Updates

    View All

    Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

    SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. "Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy," said Talat Imr

    3/25/26 4:53:16 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

    – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third

    11/6/25 4:30:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

    SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham ("Abe") Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors. "We are thrilled to welcome Abe and Vasudev to our Board of Directors as we enter an exciting new era for Rani, highlighted by both our clinical-stage pipeline and expansion opportunities into high-value therapeutics from our rece

    10/23/25 4:01:45 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Financials

    Live finance-specific insights

    View All

    Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

    - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – - Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen

    3/26/26 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listen

    3/19/26 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

    - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut

    3/31/25 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rani Therapeutics Holdings Inc.

    SC 13G - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    11/14/24 3:36:16 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Rani Therapeutics Holdings Inc.

    SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    10/17/24 4:32:40 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rani Therapeutics Holdings Inc. (Amendment)

    SC 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)

    12/8/23 4:31:53 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care